ERBB2 and breast carcinoma: Collectively, the results from these studies strongly support the notion that the basal-HER2+ phenotype may delineate a distinct entity of biologically-aggressive breast carcinomas; however, whether the basal-HER2+ phenotype also has clinical utility as a predictive marker of resistance to trastuzumab-based therapy remains to be clarified.